癌症研究
生物
肿瘤微环境
基因敲除
分子生物学
受体
流式细胞术
小干扰RNA
肿瘤坏死因子α
胰腺癌
信号转导
细胞迁移
癌变
细胞周期
RNA干扰
免疫学
趋化性
细胞生长
小发夹RNA
肿瘤进展
医学
细胞生物学
癌症
细胞
癌细胞
癌基因
自分泌信号
促炎细胞因子
白细胞介素-7受体
细胞因子
作者
Harper Margaret Marsh,Andrew Adams,Haleh Amirian,Karthik Rajkumar,Manan Patel,Luis Alberto Nivelo,Anuroop Allena,Erin M. Dickey,Elena Shersher,Kevin Van der Jeught,Anna Bianchi,Nipun B. Merchant,Jashodeep Datta
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2026-09-25
卷期号:86 (18_Supplement_2): B103-B103
标识
DOI:10.1158/1538-7445.pancreatic26-b103
摘要
Abstract INTRODUCTION: A dominant mechanism of chemoimmunotherapy resistance in PDAC is the robust infiltration and persistence of neutrophilic or polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Interleukin-1 receptor accessory protein (IL1RAP) is the co-receptor for the IL-1 superfamily cytokines which drive inflammatory signaling in PDAC. Given its preferential expression in circulating PMN-MDSCs, we sought to determine how IL1RAP orchestrates trafficking to the tumor microenvironment (TME) and PMN-MDSC pathogenicity. METHODS: Single-cell RNA sequencing (scRNA-seq) and RNA velocity analysis of tumor and spleen derived from Ptf1a Cre/+ ; Kras LSL-G12D/+ ;Tgfbr2 flox/flox (PKT) genetically engineered mouse model (GEMM) at early vs late time points was performed. In-vitro cell migration assays assessed J774M chemotaxis upon genetic or pharmacologic IL1RAP inhibition. Fluorescently labeled J774M-gCTL or J774M-Il1rap KO cells were adoptively transferred into KPC tumor-bearing mice, followed by IVIS and flow cytometric analysis. Recombinant IL33 +/- Grk2 siRNA was used to examine CXCR2 regulation. An siRNA knockdown screen identified transcriptional regulators of Grk2. Orthotopic tumor-bearing Mrp8-Cre+/- Il1rap fl/fl and control mice were used to assess tumor burden by volume and weight measurements and CXCR2/GRK2 protein expression by immunofluorescence (IF). RESULTS: ScRNA-seq with RNA velocity in PKT tumors identified Il1rap as the top trajectory-defining gene in circulating terminal-state neutrophils. Genetic ablation of Il1rap in J774M cells significantly impaired transwell migration in vitro (p<0.01). Flow cytometry demonstrated that IL-33-IL1RAP signaling selectively induced CXCR2 expression and CXCR2-dependent trafficking in IL1RAP-competent J774M cells. In vivo, adoptively transferred J774M-Il1rap KO exhibited reduced trafficking and comprised significantly fewer CXCR2+ cells that migrated to the tumor (p<0.01). IL33/IL1RAP signaling induced GRK2 downregulation (p<0.001), maintaining CXCR2 surface stability in J774M. A targeted siRNA knockdown screen identified Nfkb1 (p50) as a transcriptional repressor of Grk2. IL33/IL1RAP signaling induces p105 phosphorylation, resulting in p50/p50 mediated repression of Grk2 which maintains CXCR2 surface stability. Treatment with Grk2 siRNA +/- recombinant IL33 enhanced CXCR2 surface expression, with maximal expression observed following combined treatment. Mrp8-Cre+/- Il1rap fl/fl exhibited significantly lower tumor weights (p<0.001) and volumes (p<0.01) than control Mrp8-Cre+/- mice; this arrest in tumor growth was associated with reduced CXCR2 (p<0.05) and higher GRK2 (p<0.01) expression in Ly6G+ cells from Mrp8-Cre+/- Il1rap fl/fl spleens. CONCLUSION: IL33-IL1RAP signaling appears a critical determinant of CXCR2-dependent neutrophil trafficking in PDAC. IL1RAP signaling induces p50-mediated Grk2 repression; the resulting decline in GRK2 stabilizes CXCR2 at the cell surface, a process reversed upon IL1RAP deletion. Targeting IL1RAP may mitigate neutrophil-derived immunosuppression in PDAC. Citation Format: Harper M. Marsh, Andrew Adams, Haleh Amirian, Karthik Rajkumar, Manan Patel, Luis Nivelo, Anuroop Allena, Erin M. Dickey, Elena Shersher, Kevin Van der Jeught, Anna Bianchi, Nipun Merchant, Jashodeep Datta. Interleukin-1 Receptor Accessory Protein (IL1RAP) is a Critical Determinant of Neutrophil Trafficking in Pancreatic Cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B103.
科研通智能强力驱动
Strongly Powered by AbleSci AI